FindTrial
Sign In

Fasudil

DRUG6 trials

Sponsors

Brigham and Women's Hospital, Johns Hopkins University, Peking University Third Hospital, University Medical Center Goettingen, Woolsey Pharmaceuticals

Conditions

Alzheimer DiseaseAmyotrophic Lateral SclerosisAtherosclerosisCognitive Decline, MildCorticobasal SyndromeHypercholesterolemiaProgressive Supranuclear PalsyRaynaud

Phase 2

The Effect of Fasudil on Vascular Function in Humans
CompletedNCT00120718
Brigham and Women's HospitalAtherosclerosis, Hypercholesterolemia
Start: 2002-06-30End: 2007-01-31Target: 60Updated: 2008-09-30
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT01935518
Peking University Third HospitalAmyotrophic Lateral Sclerosis
Start: 2013-09-30End: 2015-05-31Target: 10Updated: 2013-09-06
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS
CompletedNCT03792490
University Medical Center GoettingenAmyotrophic Lateral Sclerosis
Start: 2019-02-20End: 2023-11-01Updated: 2023-11-30
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
NCT04734379
Woolsey PharmaceuticalsCorticobasal Syndrome, Progressive Supranuclear Palsy
Start: 2021-01-22End: 2023-11-30Target: 15Updated: 2022-06-03
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
RecruitingNCT06362707
Helse Stavanger HFAlzheimer Disease, Cognitive Decline, Mild
Start: 2024-08-01End: 2028-01-01Target: 200Updated: 2026-05-04

Phase 3

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
CompletedNCT00498615
Johns Hopkins UniversityRaynaud, Scleroderma
Start: 2007-04-30End: 2012-03-31Updated: 2014-11-04

Related Papers

Effects of fasudil on disease spreading in ALS - A MUNIX-based post-hoc analysis of the ROCK-ALS trial
Neurotherapeutics2026-06-04
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
2024-11-0116 citations
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)
Frontiers in Aging Neuroscience2024-02-1416 citations
Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2021-02-035 citations
Compassionate Use of the ROCK Inhibitor Fasudil in Three Patients With Amyotrophic Lateral Sclerosis
Frontiers in Neurology2020-03-1354 citations
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Frontiers in Neurology2019-03-2775 citations